Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology

Nicole Maphis, Shanya Jiang, Guixiang Xu, Olga N. Kokiko-Cochran, Saktimayee M. Roy, Linda J. Van Eldik, D. Martin Watterson, Bruce Lamb, Kiran Bhaskar

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: Hyperphosphorylation and aggregation of tau protein are the pathological hallmarks of Alzheimer's disease and related tauopathies. We previously demonstrated that the microglial activation induces tau hyperphosphorylation and cognitive impairment via activation of p38 mitogen-activated protein kinase (p38 MAPK) in the hTau mouse model of tauopathy that was deficient for microglial fractalkine receptor CX3CR1. Method: We report an isoform-selective, brain-permeable, and orally bioavailable small molecule inhibitor of p38α MAPK (MW181) and its effects on tau phosphorylation in vitro and in hTau mice. Results: First, pretreatment of mouse primary cortical neurons with MW181 completely blocked inflammation-induced p38α MAPK activation and AT8 (pS199/pS202) site tau phosphorylation, with the maximum effect peaking at 60-90 min after stimulation. Second, treatment of old (~20 months of age) hTau mice with MW181 (1 mg/kg body weight; 14 days via oral gavage) significantly reduced p38α MAPK activation compared with vehicle-administered hTau mice. This also resulted in a significant reduction in AT180 (pT231) site tau phosphorylation and Sarkosyl-insoluble tau aggregates. Third, MW181 treatment significantly increased synaptophysin protein expression and resulted in improved working memory. Fourth, MW181 administration reduced phosphorylated MAPK-activated protein kinase 2 (pMK2) and phosphorylated activating transcription factor 2 (pATF2), which are known substrates of p38α MAPK. Finally, MW181 reduced the expression of interferon-γ and interleukin-1β. Conclusions: Taken together, these studies support p38α MAPK as a valid therapeutic target for the treatment of tauopathies.

Original languageEnglish (US)
Pages (from-to)1-15
Number of pages15
JournalAlzheimer's Research and Therapy
Volume8
Issue number1
DOIs
StatePublished - Dec 15 2016

Fingerprint

p38 Mitogen-Activated Protein Kinases
Protein Isoforms
Tauopathies
Pathology
Phosphorylation
Activating Transcription Factor 2
tau Proteins
Synaptophysin
Interleukin-1
Short-Term Memory
Protein Kinases
Interferons
Alzheimer Disease
Body Weight
Inflammation
Neurons
Brain
Proteins

Keywords

  • Alzheimer's disease
  • hTau
  • MW01-10-181SRM
  • MW181 and MK2 deficiency
  • p38 MAPK inhibitor
  • p38 mitogen activated protein kinase
  • SB239063
  • tau
  • tauopathies

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Cognitive Neuroscience

Cite this

Maphis, N., Jiang, S., Xu, G., Kokiko-Cochran, O. N., Roy, S. M., Van Eldik, L. J., ... Bhaskar, K. (2016). Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology. Alzheimer's Research and Therapy, 8(1), 1-15. https://doi.org/10.1186/s13195-016-0221-y

Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology. / Maphis, Nicole; Jiang, Shanya; Xu, Guixiang; Kokiko-Cochran, Olga N.; Roy, Saktimayee M.; Van Eldik, Linda J.; Watterson, D. Martin; Lamb, Bruce; Bhaskar, Kiran.

In: Alzheimer's Research and Therapy, Vol. 8, No. 1, 15.12.2016, p. 1-15.

Research output: Contribution to journalArticle

Maphis, N, Jiang, S, Xu, G, Kokiko-Cochran, ON, Roy, SM, Van Eldik, LJ, Watterson, DM, Lamb, B & Bhaskar, K 2016, 'Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology', Alzheimer's Research and Therapy, vol. 8, no. 1, pp. 1-15. https://doi.org/10.1186/s13195-016-0221-y
Maphis, Nicole ; Jiang, Shanya ; Xu, Guixiang ; Kokiko-Cochran, Olga N. ; Roy, Saktimayee M. ; Van Eldik, Linda J. ; Watterson, D. Martin ; Lamb, Bruce ; Bhaskar, Kiran. / Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology. In: Alzheimer's Research and Therapy. 2016 ; Vol. 8, No. 1. pp. 1-15.
@article{dbc6574746b3496191d4ecb16e190530,
title = "Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology",
abstract = "Background: Hyperphosphorylation and aggregation of tau protein are the pathological hallmarks of Alzheimer's disease and related tauopathies. We previously demonstrated that the microglial activation induces tau hyperphosphorylation and cognitive impairment via activation of p38 mitogen-activated protein kinase (p38 MAPK) in the hTau mouse model of tauopathy that was deficient for microglial fractalkine receptor CX3CR1. Method: We report an isoform-selective, brain-permeable, and orally bioavailable small molecule inhibitor of p38α MAPK (MW181) and its effects on tau phosphorylation in vitro and in hTau mice. Results: First, pretreatment of mouse primary cortical neurons with MW181 completely blocked inflammation-induced p38α MAPK activation and AT8 (pS199/pS202) site tau phosphorylation, with the maximum effect peaking at 60-90 min after stimulation. Second, treatment of old (~20 months of age) hTau mice with MW181 (1 mg/kg body weight; 14 days via oral gavage) significantly reduced p38α MAPK activation compared with vehicle-administered hTau mice. This also resulted in a significant reduction in AT180 (pT231) site tau phosphorylation and Sarkosyl-insoluble tau aggregates. Third, MW181 treatment significantly increased synaptophysin protein expression and resulted in improved working memory. Fourth, MW181 administration reduced phosphorylated MAPK-activated protein kinase 2 (pMK2) and phosphorylated activating transcription factor 2 (pATF2), which are known substrates of p38α MAPK. Finally, MW181 reduced the expression of interferon-γ and interleukin-1β. Conclusions: Taken together, these studies support p38α MAPK as a valid therapeutic target for the treatment of tauopathies.",
keywords = "Alzheimer's disease, hTau, MW01-10-181SRM, MW181 and MK2 deficiency, p38 MAPK inhibitor, p38 mitogen activated protein kinase, SB239063, tau, tauopathies",
author = "Nicole Maphis and Shanya Jiang and Guixiang Xu and Kokiko-Cochran, {Olga N.} and Roy, {Saktimayee M.} and {Van Eldik}, {Linda J.} and Watterson, {D. Martin} and Bruce Lamb and Kiran Bhaskar",
year = "2016",
month = "12",
day = "15",
doi = "10.1186/s13195-016-0221-y",
language = "English (US)",
volume = "8",
pages = "1--15",
journal = "Alzheimer's Research and Therapy",
issn = "1758-9193",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology

AU - Maphis, Nicole

AU - Jiang, Shanya

AU - Xu, Guixiang

AU - Kokiko-Cochran, Olga N.

AU - Roy, Saktimayee M.

AU - Van Eldik, Linda J.

AU - Watterson, D. Martin

AU - Lamb, Bruce

AU - Bhaskar, Kiran

PY - 2016/12/15

Y1 - 2016/12/15

N2 - Background: Hyperphosphorylation and aggregation of tau protein are the pathological hallmarks of Alzheimer's disease and related tauopathies. We previously demonstrated that the microglial activation induces tau hyperphosphorylation and cognitive impairment via activation of p38 mitogen-activated protein kinase (p38 MAPK) in the hTau mouse model of tauopathy that was deficient for microglial fractalkine receptor CX3CR1. Method: We report an isoform-selective, brain-permeable, and orally bioavailable small molecule inhibitor of p38α MAPK (MW181) and its effects on tau phosphorylation in vitro and in hTau mice. Results: First, pretreatment of mouse primary cortical neurons with MW181 completely blocked inflammation-induced p38α MAPK activation and AT8 (pS199/pS202) site tau phosphorylation, with the maximum effect peaking at 60-90 min after stimulation. Second, treatment of old (~20 months of age) hTau mice with MW181 (1 mg/kg body weight; 14 days via oral gavage) significantly reduced p38α MAPK activation compared with vehicle-administered hTau mice. This also resulted in a significant reduction in AT180 (pT231) site tau phosphorylation and Sarkosyl-insoluble tau aggregates. Third, MW181 treatment significantly increased synaptophysin protein expression and resulted in improved working memory. Fourth, MW181 administration reduced phosphorylated MAPK-activated protein kinase 2 (pMK2) and phosphorylated activating transcription factor 2 (pATF2), which are known substrates of p38α MAPK. Finally, MW181 reduced the expression of interferon-γ and interleukin-1β. Conclusions: Taken together, these studies support p38α MAPK as a valid therapeutic target for the treatment of tauopathies.

AB - Background: Hyperphosphorylation and aggregation of tau protein are the pathological hallmarks of Alzheimer's disease and related tauopathies. We previously demonstrated that the microglial activation induces tau hyperphosphorylation and cognitive impairment via activation of p38 mitogen-activated protein kinase (p38 MAPK) in the hTau mouse model of tauopathy that was deficient for microglial fractalkine receptor CX3CR1. Method: We report an isoform-selective, brain-permeable, and orally bioavailable small molecule inhibitor of p38α MAPK (MW181) and its effects on tau phosphorylation in vitro and in hTau mice. Results: First, pretreatment of mouse primary cortical neurons with MW181 completely blocked inflammation-induced p38α MAPK activation and AT8 (pS199/pS202) site tau phosphorylation, with the maximum effect peaking at 60-90 min after stimulation. Second, treatment of old (~20 months of age) hTau mice with MW181 (1 mg/kg body weight; 14 days via oral gavage) significantly reduced p38α MAPK activation compared with vehicle-administered hTau mice. This also resulted in a significant reduction in AT180 (pT231) site tau phosphorylation and Sarkosyl-insoluble tau aggregates. Third, MW181 treatment significantly increased synaptophysin protein expression and resulted in improved working memory. Fourth, MW181 administration reduced phosphorylated MAPK-activated protein kinase 2 (pMK2) and phosphorylated activating transcription factor 2 (pATF2), which are known substrates of p38α MAPK. Finally, MW181 reduced the expression of interferon-γ and interleukin-1β. Conclusions: Taken together, these studies support p38α MAPK as a valid therapeutic target for the treatment of tauopathies.

KW - Alzheimer's disease

KW - hTau

KW - MW01-10-181SRM

KW - MW181 and MK2 deficiency

KW - p38 MAPK inhibitor

KW - p38 mitogen activated protein kinase

KW - SB239063

KW - tau

KW - tauopathies

UR - http://www.scopus.com/inward/record.url?scp=85006049136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006049136&partnerID=8YFLogxK

U2 - 10.1186/s13195-016-0221-y

DO - 10.1186/s13195-016-0221-y

M3 - Article

VL - 8

SP - 1

EP - 15

JO - Alzheimer's Research and Therapy

JF - Alzheimer's Research and Therapy

SN - 1758-9193

IS - 1

ER -